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Description
The purpose of this clinical practice update is to define key principles in the care of patients with chronic HCV infection who have achieved a sustained virologic response (SVR) following completion of treatment with an all-oral regimen of direct-acting antiviral agents (DAAs)
Methods
The recommendations outlined in this expert review are based on available published evidence including randomized controlled trials, observational studies, and systematic reviews, and incorporates expert opinion where applicable
Best Practice
Advice ( 
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I. Introduction
The battle against hepatitis C virus (HCV) has culminated in remarkably high rates of sustained virologic response (SVR) conferred by six currently approved interferon-free directacting antiviral (DAA) regimens against genotypes 1-6 HCV (1-6). In the many countries where these regimens are available, the use of interferon has essentially ceased. Follow-up studies and cumulative experience have affirmed that, as with earlier interferon-based therapy, SVR is tantamount to virologic cure. Fewer than 1% of patients relapse after SVR, defined during the years of interferon therapy as HCV RNA undetectability 24 weeks (SVR24), and more recently as SVR12 (7) (8) (9) (10) (11) (12) (13) .
With the increasingly frequent opportunity to celebrate virologic cure with patients comes the corresponding need to advise them about whether, when, and for how long ongoing care for liver disease is needed. Thus, it is critical to identify the ongoing risks for the individual patient and the measures needed to mitigate those risks. Numerous studies in patients cured of HCV by interferon-based therapy have demonstrated reductions in all-cause mortality, liverrelated mortality, need for liver transplantation, variceal bleeding, and hepatocellular carcinoma (14-16) as well as a reduction in mortality from extrahepatic complications (17) .
Regression of fibrosis and even cirrhosis has been documented, as has been demonstrated in other liver diseases when the underlying cause has been controlled (18) (19) (20) (21) . Nevertheless, reduction in risk is still potentially relative rather than absolute, as ongoing surveillance and intervention may be required in some patients to reduce complications arising from liver damage that has already accrued by the time SVR has been attained. Of greatest concern is the ongoing risk of HCC in patients with pre-existing advanced fibrosis or cirrhosis. In this paper, M A N U S C R I P T
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the considerations surrounding the care of patients who have achieved SVR will be discussed, and proposed recommendations will be presented.
II. Assessment of HCV RNA after SVR12 has been attained
With the initiation of trials of DAA regimens, initially in combination with interferon and later without it, the attainment of SVR 12 weeks after completion of treatment replaced SVR24 as the primary endpoint, defined as undetectable HCV RNA on a highly sensitive PCR assay (lower limit of detection <12 IU/mL). This transition was based upon the rarity of relapse after followup week 12, and it helped move the field ahead by shortening the intervals between successive trials in development programs (22) . It has become apparent that late relapse beyond this time point is no more common, and perhaps less so, than it was after interferon-based therapy (<1%) (7-10, 12-13, 23-24) . For example, in a preliminary report of long term outcomes in patients treated with ledipasvir/sofosbuvir, none of 1850 patients relapsed between the 12 th and 24 th week of follow-up (24) . As a result, the AASLD/IDSA Guidance document (25) has suggested that patients do not require another HCV RNA determination after SVR12, and can be dismissed from ongoing follow-up if they had Metavir F0-F2 fibrosis before treatment.
Recent data indicate, however, that late relapse can indeed occur in the absence of de novo reinfection. In a series of 1054 patients who achieved SVR12 after receiving a course of paritaprevir/ritonavir/ombitasvir and dasabuvir, representing 97% of patients treated in six pivotal trials, 5 (0.5%) had subsequent virologic failure, shown by phylogenetic analysis to be relapse in 4 patients (3 by post-treatment week 24, and 1 by post-treatment week 48), and reinfection in 1 patient. All virologic failures occurred in GT1a patients (13) . In another study of M A N U S C R I P T
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3004 patients receiving sofosbuvir-containing therapy, mostly without interferon, 3004 patients had SVR24, while 12 had reappearance of HCV RNA by follow-up week 24. Seven of the 12 were shown to have reinfection by phylogenetic analyses of either full-length or short fragment NS5B sequencing, while 5 patients (0.2%) demonstrated late relapse with the same virus (12) .
Although the risk of late relapse appears to be very low, some clinicians may feel it prudent to obtain another HCV RNA assay at follow-up week 24 and/or follow-up week 48 (the latter as recommended in the EASL Guidelines) (26) , rather than stopping monitoring after SVR12 (25) .
There is no evidence at present that any particular viral genotype or patient type is more prone to this rare phenomenon. Registries pursuant to several of the pivotal trial programs are further evaluating this issue, and refinement of these recommendations may be appropriate at a future time. It should be noted that, using viral sequencing, relapse as late as 6-8 years of follow-up had historically been described after interferon therapy (27) (28) , but this has not been reported after DAA therapy and the extreme rarity of this occurrence, if it exists at all, does not presently justify late surveillance for viral reappearance years after DAA therapy.
III. Ongoing surveillance for hepatocellular carcinoma after SVR
HCC is strongly associated with established cirrhosis, occurring in 1-4% of patients with HCVassociated cirrhosis annually (29 severe alcohol use. In another study of 307 patients, highly significant reductions in cumulative incidence of both liver cancer and liver-related complications were observed (15) . Reduction in all-cause mortality in patients who achieve SVR has been observed even in the absence of baseline cirrhosis in a large U.S. Veterans Administration database (14) . Ultrasound is the recommended imaging modality for hepatoma surveillance in both the AASLD Guidelines for hepatocellular carcinoma, and the AASLD/IDSA HCV guidance document (26, 36) . This recommendation is based upon considerations of cost-effectiveness and the historical use of ultrasound in studies that have shown an impact on outcome of early detection
of HCC. However, both CT and MRI compare favorably to ultrasound with regard to sensitivity for small HCCs, particularly in cirrhotic patients (37) . Moreover, obesity and overlying bowel gas may impair the accuracy of ultrasound, and it is not uncommon to receive a radiologic report containing a recommendation to pursue an alternate imaging modality, leaving the clinician and patient in a potentially vulnerable position if the recommended imaging studies are not pursued. Patient-centered approaches are needed to balance the benefits and risks of contrast-enhanced cross-sectional imaging studies such as triphasic CT scan or MRI, which should be considered carefully, especially in patients with obesity, "indeterminate" lesions, or those in for whom liver ultrasound provides inadequate visualization of the liver parenchyma.
Despite its greater cost than CT, MRI has the advantage of avoiding exposure to ionizing radiation. Strategies such as alternating MRI and liver ultrasound are commonly used in clinical practice, although require further evidence to be incorporated into formal guideline recommendations. Many radiologists recommend the routine use of gadoxeate (Eovist) rather than gadolinium contrast for HCC screening with MRI because of the superior enhancement of liver parenchyma with the former in patients with cirrhosis (38) .
Although the risk of HCV-associated HCC is highest in patients with cirrhosis, HCC may also occur in patients with bridging fibrosis (39) . In some cases, this may be attributable to undersampling of the liver on biopsy or transition to cirrhosis after F3 fibrosis was present initially (40) . Based on available evidence for the risk of HCC in this group, HCC surveillance recommendations for patients with cirrhosis (liver ultrasound ± AFP twice per year) have been applied to patients with F3 fibrosis (25, 26) ; the authors concur with this recommendation.
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IV. Is HCC risk after SVR exclusive to patients with advanced fibrosis and cirrhosis?
In determining whether a patient needs post-SVR HCC screening, the distinction between "moderate" fibrosis (e.g. Metavir F2) and "advanced" fibrosis (F3/4) may not be easily defined.
Moreover, it remains possible that even patients with mild or moderate fibrosis may on rare occasion develop HCC. This suggestion has emerged most strongly from a large series of patients with SVR after interferon therapy in Japan. In the study by Yamashita et al (32) , 42% of patients who developed HCC among a cohort of 562 SVR patients followed for a median of 4. Based upon the available evidence, routine screening for HCC in patients with F0-2 fibrosis is not recommended after SVR, although some clinicians may choose to obtain a final ultrasound during the year after SVR following DAA therapy. Should additional data from "real-world" cohorts confirm the emergence of late HCC in F0-2 patients post-SVR, screening recommendations will require reconsideration.
V.
Can HCC surveillance ever be discontinued?
Lifelong surveillance for HCC among patients with advanced fibrosis and cirrhosis entails substantial psychological and economic implications, as well as investments of time for both patients and clinicians. As evidence continues to accumulate that fibrosis regression may occur in many patients who achieve an SVR (18) (19) (20) (21) , it is conceivable that the risk of HCC could eventually decline to a point at which surveillance becomes unnecessary.
Unfortunately, there is relatively limited evidence supporting a correlation between measurable regression of cirrhosis as determined histologically and reduction of HCC risk. In a more recent study in 97 SVR patients with paired liver biopsies, the stage of liver fibrosis regressed in 44 patients (45%) and progressed in only six patients (6%) at a mean 5.8 years after treatment. HCC was significantly more frequent in patients with progressive fibrosis than in those in whom fibrosis regressed or was stable (cumulative incidence 33% vs 4% at 5 years, P < 0.05) (19) .
Suggestive as these studies are, post-SVR liver biopsies are not routinely performed and are not clinically practical, and it is unlikely that data derived from serial post-SVR liver biopsies will be sufficiently robust to establish whether discontinuation of HCC surveillance can be Based on their cumulative data, the authors cautioned against performing liver stiffness measurements to follow regression of fibrosis or cirrhosis (52) . A study from Taiwan of 278 patients with SVR with a median follow-up period of 7.6 years, comprised of both non-cirrhotic Although the issue of recurrent HCC after SVR requires further study, at present there is insufficient evidence to warrant a change in surveillance strategy for such patients, nor is there sufficient evidence to suggest that DAA therapy should be withheld in patients who have undergone locoregional therapy for HCC previously. Some clinicians might choose to consider intensification of imaging frequency to every three months for a year after completion of HCV treatment, perhaps depending on the time elapsed since treatment of HCC and the level of confidence that the tumor had been ablated.
IX. Reinfection
The high prevalence of HCV infection in intravenous drug users has aroused intense interest in targeting this population for treatment with DAA therapy. Even in the interferon era, when many clinicians were reluctant to treat such patients, centers with expertise in the management of these patients had demonstrated good results with interferon therapy (72) . A recent study confirmed that treatment of HCV with grazoprevir/elbasvir is feasible and associated with high SVR (97%) in patients treated within addiction treatment centers, many of whom were documented to have used illicit drugs actively during their HCV treatment (73) .
However, confirmed reinfection on population sequencing and phylogenetic analysis was 
X. Lifestyle Measures
Although many patients who achieve SVR have a favorable clinical course, which may include regression of liver fibrosis, some patients may experience fibrosis progression,, hepatic decompensation, and/or hepatocellular carcinoma, with HCC the dominant persistent risk in SVR patients in the absence of concomitant liver disease. Long-term observational data addressing liver-related outcomes in patients post-SVR with oral DAA regimens are lacking.
Available data in patients undergoing interferon-based therapy suggest that individuals who achieve SVR may continue to experience a higher mortality rate than the general population (77) (78) , even among non-cirrhotic patients who achieve SVR, with a significant contribution in the latter group from drug-related causes (79) . As such, although most excess liver-related outcomes may be seen in patients with advanced liver fibrosis or cirrhosis due to persistent risk of liver cancer, all patients achieving SVR should undergo evaluation for modifiable risk factors M A N U S C R I P T
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for liver injury such as alcohol, drug use, fatty liver, and diabetes mellitus. The impact of alcohol consumption on liver fibrosis progression and HCC risk in context of ongoing chronic hepatitis C infection is well documented, and even non-hazardous or low to moderate alcohol intake is associated with an increased risk of liver-related outcomes (80) (81) . Based on limited data in patients with eradication of HCV post-SVR, alcohol persists as a risk factor for all-cause mortality (77) . No safe limit for alcohol consumption has been established post-SVR, and therefore avoidance of significant alcohol intake should be recommended for all patients, and complete abstinence is prudent in patients with advanced liver fibrosis or cirrhosis. Diabetes and fatty liver are commonly present in patients with chronic hepatitis C and may develop de novo or persist long-term as risk factors for liver fibrosis progression and HCC post-SVR.
Diabetes has been confirmed to represent an important risk factor for HCC in patients with chronic HCV infection, and appears to remain a risk factor for cirrhosis-related complications including HCC post-SVR (34, (82) (83) as well as HCC risk in non-cirrhotic patients (84) . Fatty liver has independently demonstrated to represent a possible risk factor for liver fibrosis progression (85) and HCC (86) in patients who have achieved SVR following antiviral therapy. Until more data become available to provide evidence-based recommendations for addressing diabetes and fatty liver in patients post-SVR, patients at risk or with a known diagnosis should be advised of the risk of liver-related complications, and continue disease-specific management to optimize weight loss and glycemic control.
XI. Conclusions
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With the marked increase in number of patients who achieve SVR with present direct-acting antiviral regimens for hepatitis C, there is a need to promote a broad-based understanding among clinicians regarding which patients can be discharged from further HCV-related care, the criteria that define a need for ongoing management, and the elements and duration of that management. We have herein proposed guidelines for management of the post-SVR patient representing a synthesis of the latest available evidence with expert opinion. Most of the published evidence and experience about long-term outcomes after SVR are derived from studies of interferon-based therapy. It is appropriate at present to formulate recommendations based upon that experience, but we expect and encourage large long-term studies of outcomes after interferon-free DAA therapy which will further refine our concepts of 
